Name Description
blinatumomab a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma
TCRDv4.6.0
DrugCentral Indication
DrugCentral
blinatumomab